CARVYKTI: Uses, Dosage & Side Effects
A BCMA-directed CAR-T cell therapy for adults with relapsed or refractory multiple myeloma – a personalized, one-time treatment made from the patient’s own genetically modified T cells
CARVYKTI (ciltacabtagene autoleucel, also known as cilta-cel) is a groundbreaking CAR-T cell therapy used to treat adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. Unlike conventional drugs, CARVYKTI is a personalized medicine manufactured from each individual patient’s own T cells, which are genetically engineered in a laboratory to recognize and destroy myeloma cells. The treatment is administered as a single intravenous infusion at a qualified treatment center and requires close monitoring for several weeks afterward. CARVYKTI represents a major advance in the treatment of multiple myeloma, with clinical trials demonstrating deep and durable responses in patients who had exhausted other options.
Quick Facts: CARVYKTI
Key Takeaways
- CARVYKTI is a personalized, one-time CAR-T cell therapy in which the patient’s own T cells are genetically modified to target BCMA (B-cell maturation antigen) on myeloma cells, offering a novel mechanism for treating relapsed or refractory multiple myeloma.
- The treatment process spans approximately 5–6 weeks – from T-cell collection (leukapheresis) through manufacturing, lymphodepleting chemotherapy, and a single intravenous infusion that typically takes less than 60 minutes.
- Cytokine release syndrome (CRS) occurs in the majority of patients and can be life-threatening; patients must remain near the treatment center for at least 4 weeks after infusion and visit the hospital daily for the first 14 days.
- CARVYKTI carries risks of serious neurological effects including ICANS (immune effector cell-associated neurotoxicity) and parkinsonism-like movement disorders that may appear days to weeks after infusion.
- After receiving CARVYKTI, patients cannot donate blood, organs, or tissues, may receive false-positive HIV test results, must avoid live vaccines during immune recovery, and are enrolled in a 15-year long-term follow-up registry.
What Is CARVYKTI and What Is It Used For?
CARVYKTI belongs to a new class of medicines known as genetically modified cell therapies. It is fundamentally different from traditional pharmaceutical drugs: rather than being manufactured in a factory using chemical or biological processes, CARVYKTI is custom-made for each individual patient from their own white blood cells (T cells). These T cells are collected from the patient’s blood, sent to a specialized manufacturing facility, and genetically engineered to produce a protein called a chimeric antigen receptor (CAR) on their surface. Once infused back into the patient, these CAR-T cells act as “living drugs” that can seek out and kill cancer cells.
The CAR engineered into CARVYKTI is designed to target B-cell maturation antigen (BCMA), a protein that is highly expressed on the surface of multiple myeloma cells but largely absent from other healthy tissues. What makes CARVYKTI’s design distinctive is its use of two single-domain antibodies (also called VHH nanobodies or camelid-derived antibodies) that bind to two different regions (epitopes) of the BCMA protein. This dual-epitope binding approach provides exceptionally strong (high-avidity) attachment to myeloma cells, making it difficult for cancer cells to evade detection even if they try to downregulate BCMA expression.
When the CAR on CARVYKTI cells engages BCMA on a myeloma cell, it triggers a cascade of immune signaling events within the T cell. The intracellular signaling domains of the CAR – which include a 4-1BB costimulatory domain and a CD3-zeta activation domain – instruct the T cell to activate, proliferate, and mount a powerful cytotoxic response. The activated CAR-T cells then directly kill the targeted myeloma cell through the release of cytotoxic granules (perforin and granzymes) and through other immune mechanisms. Importantly, after killing their targets, the CAR-T cells continue to expand and persist in the body, providing ongoing immunosurveillance against any remaining or recurring BCMA-expressing myeloma cells.
CARVYKTI is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and regulatory authorities in multiple other countries for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including an immunomodulatory agent and a proteasome inhibitor, and have demonstrated disease progression on the last therapy. In the pivotal CARTITUDE-1 and CARTITUDE-4 clinical trials, CARVYKTI demonstrated remarkable efficacy with overall response rates exceeding 95% and a significant proportion of patients achieving stringent complete responses.
Multiple myeloma is a cancer of plasma cells – a type of white blood cell normally responsible for producing antibodies. In multiple myeloma, abnormal plasma cells accumulate in the bone marrow, crowding out healthy blood cells and producing abnormal proteins that can damage the kidneys and other organs. Despite significant advances in treatment over the past two decades, multiple myeloma remains largely incurable, and most patients eventually relapse after each line of therapy. CAR-T cell therapies like CARVYKTI represent a paradigm shift in treatment, offering the possibility of deep, durable remissions for patients with limited remaining options.
Unlike conventional drugs that are mass-produced, each dose of CARVYKTI is manufactured individually for a specific patient from their own T cells. This autologous (self-derived) approach means the treatment cannot be given to another person. The entire process from blood collection to infusion takes approximately 5–6 weeks, and the patient may receive bridging therapy (other myeloma treatments) during the manufacturing period to keep the disease under control.
What Should You Know Before Receiving CARVYKTI?
Contraindications
CARVYKTI must not be given to patients who have a known allergy (hypersensitivity) to ciltacabtagene autoleucel or to any of the other ingredients in the product, including dimethyl sulfoxide (DMSO), a cryopreservation agent used to store the frozen cells. Additionally, patients who are allergic to any components of the lymphodepleting chemotherapy regimen administered before CARVYKTI must not receive the treatment, as lymphodepletion is an essential preparatory step.
Warnings and Precautions
CRS is a very common and potentially life-threatening immune reaction that occurs in the majority of patients who receive CARVYKTI. It is caused by the massive activation of CAR-T cells and the resulting release of large amounts of cytokines (inflammatory proteins) into the bloodstream. Symptoms include high fever, chills, rapid heartbeat, difficulty breathing, and dangerously low blood pressure. CRS typically develops within 1–14 days after infusion and requires immediate medical management, often with tocilizumab (an IL-6 receptor blocker), corticosteroids, and intensive supportive care.
CARVYKTI can cause serious neurological effects including immune effector cell-associated neurotoxicity syndrome (ICANS) with confusion, disorientation, difficulty speaking, reduced consciousness, and anxiety. Additionally, CARVYKTI has been uniquely associated with parkinsonism-like movement disorders presenting as slow movements, tremor, changes in handwriting, and reduced facial expression. These neurological events may appear days to weeks after infusion and may be progressive. Seek immediate medical attention if any neurological symptoms develop.
Before and during treatment with CARVYKTI, tell your doctor if any of the following apply to you:
- Current or previous nervous system problems: Including seizures, stroke, new or worsening memory loss, or any neurodegenerative conditions. These may increase the risk of neurological complications.
- Heart, lung, or blood pressure problems: CRS can significantly affect cardiovascular function, and pre-existing cardiac or pulmonary conditions may increase the severity of these reactions.
- Liver or kidney problems: Organ function may be affected by the treatment, and pre-existing impairment may alter the risk profile.
- Active infections: Any current infection must be treated and resolved before CARVYKTI can be administered. The lymphodepleting chemotherapy and the CAR-T cells themselves cause significant immunosuppression.
- Signs of graft-versus-host disease (GVHD): If you have previously received a donor stem cell transplant, you may be at risk for GVHD, where transplanted cells attack your body causing skin rash, nausea, vomiting, diarrhea, and bloody stools.
- Secondary malignancies: There have been reports of patients developing new cancers, including blood cell cancers, after treatment with CARVYKTI and similar CAR-T cell products. Tell your doctor about any new swelling in lymph nodes or changes in the skin.
Pre-Treatment Tests and Monitoring
Before you receive CARVYKTI, your doctor will conduct a thorough evaluation including complete blood count, cardiac and pulmonary function assessments, screening for hepatitis B, hepatitis C, and HIV, assessment of cancer status, and review of vaccination history. After treatment, your doctor will regularly monitor your blood counts, as prolonged low blood cell counts (cytopenias) are common and may last for weeks to months following CARVYKTI infusion.
Children and Adolescents
CARVYKTI is not approved for use in children and adolescents under 18 years of age. The safety and efficacy of the treatment have not been studied in this age group.
Pregnancy and Breastfeeding
The effects of CARVYKTI on pregnancy and breastfeeding are not known. If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before receiving this treatment. A pregnancy test must be performed before treatment begins, and CARVYKTI should only be administered if the test confirms you are not pregnant. If you become pregnant or think you may be pregnant after receiving CARVYKTI, contact your doctor immediately.
Driving and Operating Machinery
CARVYKTI can significantly affect your ability to drive vehicles or operate tools and machinery due to fatigue, confusion, balance problems, dizziness, and reduced alertness. You must not drive or operate machinery for at least 8 weeks after receiving CARVYKTI, and should refrain for longer if any of these symptoms persist or recur.
Important Information About Ingredients
CARVYKTI contains dimethyl sulfoxide (DMSO), a cryopreservation agent, and may contain trace amounts of kanamycin (an aminoglycoside antibiotic used during manufacturing). Both substances can occasionally cause allergic reactions. Your healthcare team will monitor you for any signs of an allergic reaction during and after infusion.
How Does CARVYKTI Interact with Other Drugs?
Because CARVYKTI is a living cell therapy rather than a conventional chemical drug, its interactions with other medications differ from those of traditional pharmaceuticals. The primary concern is that drugs that suppress the immune system may interfere with the ability of the CAR-T cells to expand, persist, and effectively target myeloma cells.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Corticosteroids (e.g., dexamethasone, prednisone) | May suppress CAR-T cell expansion and activity if given before or shortly after infusion | Avoid before infusion; used therapeutically for CRS/ICANS management after infusion |
| Live vaccines (e.g., MMR, varicella, BCG, yellow fever) | Risk of uncontrolled infection due to severe immunosuppression | Contraindicated for at least 6 weeks before lymphodepletion and during immune recovery |
| Immunosuppressive agents (e.g., cyclosporine, mycophenolate) | May reduce CAR-T cell persistence and efficacy | Discuss timing and necessity with your treatment team |
| Lymphodepleting chemotherapy (fludarabine + cyclophosphamide) | Required pre-treatment to create favorable conditions for CAR-T cell expansion | Mandatory part of the CARVYKTI treatment protocol |
Minor Interactions and Considerations
- Intravenous immunoglobulin (IVIG): Many patients develop low antibody levels after CARVYKTI and may require IVIG replacement therapy. This is a supportive measure, not a drug interaction.
- Anti-infective agents: Prophylactic antibiotics, antivirals, and antifungals are commonly used after CARVYKTI to prevent opportunistic infections and do not interfere with CAR-T cell function.
- Tocilizumab: This IL-6 receptor antagonist is the first-line treatment for CRS and should be readily available at the treatment facility before infusion begins.
- Antihistamines and paracetamol (acetaminophen): Commonly given 30–60 minutes before CARVYKTI infusion as premedication to reduce infusion-related reactions.
Always provide your healthcare team with a complete list of all medications, including over-the-counter drugs, vitamins, and herbal supplements, before beginning the CARVYKTI treatment process.
What Is the Correct Dosage of CARVYKTI?
The Treatment Process
Step 1: Leukapheresis (T-Cell Collection)
Your doctor will collect some of your blood using a catheter placed in a vein. A machine separates the white blood cells from the rest of your blood, which is returned to you through the vein. This process takes approximately 3–6 hours and may need to be repeated. The collected white blood cells are then shipped to a manufacturing facility.
Step 2: Manufacturing (Approximately 4 Weeks)
At the manufacturing facility, your T cells are genetically modified to express the BCMA-targeting chimeric antigen receptor. The modified cells are expanded, tested for quality and safety, and then cryopreserved (frozen) for shipment back to your treatment center. During this period, you may receive bridging therapy to keep your myeloma under control.
Step 3: Lymphodepleting Chemotherapy (3 Days Before Infusion)
A few days before receiving CARVYKTI, you will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide for 3 consecutive days. This reduces your existing white blood cells to create a favorable environment for the new CAR-T cells to expand.
Step 4: CARVYKTI Infusion (Day 0)
CARVYKTI is given as a single intravenous infusion, typically taking less than 60 minutes. You may receive premedication with antihistamines and paracetamol 30–60 minutes beforehand. Your healthcare team will verify that the product matches your identity before administration. This is a one-time treatment.
Adults
| Parameter | Details |
|---|---|
| Target dose | 3.2 × 106 to 1 × 108 CAR-positive viable T cells |
| Volume | 30 mL or 70 mL dispersion per infusion bag |
| Route | Intravenous infusion |
| Infusion duration | Typically less than 60 minutes |
| Number of doses | Single dose (one-time treatment) |
Children
CARVYKTI is not approved for patients under 18 years of age. There is no established pediatric dose.
Elderly
No specific dose adjustments are required based on age alone. CARVYKTI has been studied in patients across a wide age range, including those over 65 years. However, elderly patients may be more susceptible to certain side effects.
After Infusion: Monitoring Requirements
- Stay near the hospital: You must remain within close proximity of the treatment center for at least 4 weeks after receiving CARVYKTI.
- Daily hospital visits: You are required to visit the hospital every day for at least 14 days after infusion for monitoring.
- Hospitalization if needed: Serious side effects such as CRS or neurological problems may require hospital admission until symptoms are controlled.
- Long-term follow-up: You will be enrolled in a registry study for at least 15 years to monitor long-term effects.
Overdose
Because CARVYKTI is prepared as a single, patient-specific dose and administered by healthcare professionals in a controlled setting, overdose in the traditional sense is not applicable. An excessive immune response (severe CRS or neurotoxicity) is managed with tocilizumab, corticosteroids, and intensive supportive care.
What Are the Side Effects of CARVYKTI?
Like all medicines, CARVYKTI can cause side effects, although not everyone experiences all of them. Because CARVYKTI is a living cell therapy that activates the immune system, many of its side effects are related to the intense immune response it triggers. Some side effects can be serious or life-threatening and require immediate medical attention.
CRS is a severe immune reaction that can be life-threatening. Signs include fever (38°C or higher), chills, rapid heartbeat, difficulty breathing, and low blood pressure causing dizziness. CRS typically occurs within 1–14 days after infusion and requires urgent medical management with tocilizumab and supportive care.
Watch for confusion, disorientation, anxiety, memory loss, difficulty speaking or slurred speech, slow movements, changes in handwriting, reduced facial expression, and loss of coordination. These may be signs of ICANS or parkinsonism. Report any new neurological symptoms immediately.
CARVYKTI increases the risk of serious, potentially fatal infections due to profound immunosuppression. There have also been reports of patients developing new cancers, including blood cell cancers, after treatment. Report any new symptoms, unexplained swelling, or skin changes to your doctor.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Cytokine release syndrome (CRS) – fever, chills, rapid heartbeat, low blood pressure, difficulty breathing
- Neurological effects – confusion, disorientation, anxiety, memory loss, difficulty speaking, slow movements
- Low white blood cell counts (neutropenia, lymphopenia)
- Low platelet counts (thrombocytopenia) and low red blood cell counts (anemia)
- Infections – upper respiratory tract, pneumonia, viral infections
- Low immunoglobulin (antibody) levels
- Low blood oxygen levels (hypoxia)
- Elevated blood pressure
- Bleeding, which may be severe
- Fatigue and general weakness
- Nausea, decreased appetite, constipation, vomiting, diarrhea
- Headache, sleep problems
- Pain, including muscle and joint pain
- Cough, shortness of breath
- Swelling due to fluid retention
- Nerve damage causing tingling, numbness, or pain
- Muscle spasms, muscle stiffness
- Low calcium, sodium, potassium, magnesium, and phosphate levels
- Low albumin levels
- Blood clotting problems
- Elevated ferritin, gamma-glutamyltransferase, and transaminase levels
Common
May affect up to 1 in 10 people
- Febrile neutropenia (low white blood cells with fever)
- Gastroenteritis, immune-mediated enterocolitis
- Abdominal pain
- Urinary tract infection
- Fungal infection
- Increased lymphocyte count
- Sepsis (severe infection throughout the body)
- Kidney failure
- Abnormal heart rhythm
- Hemophagocytic lymphohistiocytosis (HLH)
- Capillary leak syndrome
- Elevated alkaline phosphatase levels
- Muscle tremor, mild muscle weakness from nerve damage
- Severe confusion
- Facial numbness, difficulty moving facial and eye muscles
- Elevated bilirubin levels
- Blood clots
- Skin rash
- Elevated C-reactive protein levels
- A new type of cancer originating from blood cells
Uncommon
May affect up to 1 in 100 people
- Tingling, numbness, and pain in hands and feet with difficulty walking, limb weakness, and breathing difficulties (Guillain-Barré-like syndrome)
- A new type of cancer originating from T cells (secondary T-cell malignancy)
If you experience any of the side effects listed above, tell your doctor or nurse immediately. Do not attempt to treat symptoms on your own. Report any side effects even after the initial monitoring period, as some effects may develop weeks or months after CARVYKTI infusion.
How Should CARVYKTI Be Stored?
CARVYKTI requires highly specialized storage conditions available only at qualified treatment centers. The product is stored in the vapor phase of liquid nitrogen at a temperature of −120°C (−184°F) or below. The frozen cells are contained in a cryopreservation cassette that protects the infusion bag during storage and transport.
When it is time for treatment, the CARVYKTI infusion bag is thawed at 37°C using either a water bath or a controlled thawing device, and must be completed within 15 minutes. Once thawed, CARVYKTI must be administered within 2.5 hours and cannot be re-frozen or refrigerated. The entire thawing and infusion process is carefully coordinated to ensure maximum cell viability.
Patients do not need to handle or store CARVYKTI themselves. All aspects of storage, thawing, preparation, and administration are managed by specialized healthcare professionals at the treatment facility.
What Does CARVYKTI Contain?
Each CARVYKTI infusion bag contains ciltacabtagene autoleucel, which consists of the patient’s own T cells genetically modified using a lentiviral vector to express a chimeric antigen receptor directed against BCMA. The cell dispersion contains between 3.2 × 106 (3.2 million) and 1 × 108 (100 million) CAR-positive viable T cells.
The infusion bag contains either 30 mL or 70 mL of cell dispersion, supplied in either a 50 mL or 250 mL infusion bag individually packaged in an aluminum cryocassette. The dispersion appears colorless to white, and may include shades of yellow or pink.
The other ingredient is CryoStor CS5, a cryopreservation solution containing dimethyl sulfoxide (DMSO) as the principal cryoprotectant. The product may also contain trace amounts of kanamycin, an aminoglycoside antibiotic used during manufacturing. This medicine contains genetically modified human cells.
What Should You Know After Receiving CARVYKTI?
CARVYKTI is not a conventional medicine that leaves your body after a short time. The genetically modified T cells persist in your bloodstream and tissues, which has several important long-term implications:
- Blood and organ donation: After receiving CARVYKTI, you must not donate blood, organs, tissues, or cells for transplantation. The genetically modified cells could potentially be transferred to a recipient.
- HIV testing: Commercial HIV tests may give a false-positive result because the genetic modification involves a lentiviral vector, and some HIV tests may detect components of this vector. You remain HIV-negative despite the result. Inform all healthcare providers about your CARVYKTI treatment if you need HIV testing.
- Vaccination: Live vaccines must not be given during immune recovery after CARVYKTI. Your doctor will advise you on when it is safe to resume vaccinations. Inactivated vaccines may be given according to your doctor’s guidance.
- Long-term follow-up: You will be asked to participate in a registry study for at least 15 years after treatment to monitor your health and detect any late effects of the gene-modified cell therapy.
Ensure that all healthcare providers you see in the future are aware that you have received CARVYKTI, as this information is relevant to your ongoing medical care.
Frequently Asked Questions About CARVYKTI
CARVYKTI (ciltacabtagene autoleucel) is a CAR-T cell therapy used to treat adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. It is a personalized, one-time treatment made from the patient’s own T cells, which are genetically modified to recognize and destroy myeloma cells expressing the BCMA protein.
Unlike chemotherapy, which uses chemical drugs to kill rapidly dividing cells (affecting both cancer and healthy cells), CAR-T cell therapy uses the patient’s own immune cells genetically modified to specifically target cancer cells. CARVYKTI is a “living drug” that can multiply inside the body and persist over time. Chemotherapy requires multiple cycles, whereas CARVYKTI is a single, one-time infusion.
CRS is a widespread immune reaction that occurs when activated CAR-T cells rapidly release large amounts of inflammatory proteins (cytokines). It is very common, affecting the majority of patients. Symptoms range from mild (fever, chills) to severe (low blood pressure, difficulty breathing, organ dysfunction). It typically develops within 1–14 days after infusion and is managed primarily with tocilizumab, corticosteroids, and intensive supportive care.
The total treatment process takes approximately 5–6 weeks. T cells are collected via leukapheresis (3–6 hours), shipped and manufactured over about 4 weeks, followed by 3 days of lymphodepleting chemotherapy, then a single infusion (under 60 minutes). After infusion, you must remain near the hospital for at least 4 weeks with daily visits for the first 14 days. The total commitment, including recovery, is approximately 2–3 months.
Yes. ICANS may cause confusion, difficulty speaking, disorientation, and reduced consciousness. Parkinsonism-like symptoms may include slow movements, tremor, changes in handwriting, and a mask-like facial expression. These effects may develop days to weeks after infusion. Patients with pre-existing neurological conditions may face higher risks. Any new neurological symptoms should be reported immediately.
CARVYKTI is manufactured using a lentiviral vector – a modified, harmless virus – to deliver the CAR gene into your T cells. Some commercial HIV tests detect genetic material similar to components of this vector, resulting in a false-positive. This does not mean you have HIV. Inform all healthcare providers about your CARVYKTI treatment so appropriate confirmatory tests are used.
References
- European Medicines Agency (EMA). CARVYKTI (ciltacabtagene autoleucel) – Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu/EPAR/carvykti
- U.S. Food and Drug Administration (FDA). CARVYKTI (ciltacabtagene autoleucel) – Prescribing Information. Revised 2024. Available at: fda.gov/carvykti
- San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335–347. doi:10.1056/NEJMoa2303379 (CARTITUDE-4 trial)
- Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1). Lancet. 2021;398(10297):314–324. doi:10.1016/S0140-6736(21)00933-8
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 2.2025.
- Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines. Ann Oncol. 2024;35(6):572–597.
- Cohen AD, Parekh S, Engel AM, et al. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2024 Update. Am Soc Clin Oncol Educ Book. 2024;44:e432101.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
Editorial Team
Medical Writing
iMedic Medical Editorial Team – Specialists in Hematology, Oncology, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel of board-certified physicians following GRADE evidence framework
Sources
EMA SmPC, FDA Prescribing Information, NCCN Guidelines, ESMO Guidelines, peer-reviewed clinical trial publications
Quality Standards
Evidence Level 1A – Based on systematic reviews and randomized controlled trials. No commercial funding or pharmaceutical sponsorship.